ClinicalTrials.gg
RecruitingNCT06019975PEAUpdated Mar 24, 2026

FDG-PET in the Diagnosis of Autoimmune Encephalitis

An observational study in Autoimmune Encephalitis, sponsored by University of Milano Bicocca. Recruiting at 6 sites in Italy. Per ClinicalTrials.gov, last updated 2026-03-24.

Sponsored by University of Milano Bicocca · Observational

How we know

From the registry’s dates

  • Started Mar 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
90
Sex
All
01

Study summary

The goal of this retrospective observational study is to compare brain fluorodeoxyglucose-positron emission tomography (FDG-PET) of patients with autoimmune encephalitis, normal controls and patients with Alzheimer's disease (AD). The main question it aims to answer is:

•is there a specific pattern of brain metabolism in patients with autoimmune encephalitis Participants data and images will be retrospectively collected from hospital records, and FDG-PET images will be analyzed by means of statistical parametric mapping (SPM). Controls will be selected from validated public databases.

02

Conditions studied

  • Autoimmune Encephalitis

Keywords

  • Autoimmune Encephalitis
  • FDG-PET
  • SPM
03

In context

Autoimmune Diseases of the Nervous System

123 studies on the registry are indexed under Autoimmune Diseases of the Nervous System; 59 are open to participants now.

This study's planned enrollment of 90 is below the median of 160 across 57 observational studies indexed under Autoimmune Diseases of the Nervous System.

Browse Autoimmune Diseases of the Nervous System studies →

Lead sponsor

University of Milano Bicocca is the lead sponsor of 126 studies on the registry; 47 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with autoimmune encephalitis admitted to the recruiting centers

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of encephalitis according to clinical criteria
  • Brain magnetic resonance imaging performed between clinical presentation and treatment
  • Cerebrospinal fluid analysis performed between clinical presentation and treatment
  • Brain FDG-PET performed between clinical presentation and treatment
  • Autoantibodies testing performed between clinical presentation and treatment

Exclusion criteria

Exclusion Criteria:

  • Refusal to give consent for the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
90 participants (estimated)
Patient registry
No

Groups and cohorts

  • Autoimmune Encephalitis patients

    Patients with autoimmune encephalitis admitted to the centers, who underwent a brain FDG-PET during the course of their disease trajectory.

    Diagnostic Test: FDG-PET

Interventions

  • Diagnostic testFDG-PET

    Brain FDG-PET

06

What researchers measure

Primary outcomes

  1. SPM analysis of brain metabolic pattern

    Pattern of brain metabolism in patients with autoimmune encephalitis compared with healthy controls and patients with Alzheimer's disease, drawn from validated published databases

    Time frame: up to 6 months

Secondary outcomes

  1. Sensitivity of basal ganglia hypermetabolism

    Sensitivity of basal ganglia hypermetabolism for the diagnosis of autoimmune encephalitis

    Time frame: up to 6 months

  2. Diagnostic delay

    Comparison of diagnostic delay with and without FDG-PET

    Time frame: up to 6 months

07

Study locations

2 of 6 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2023 (actual). Primary completion is estimated for Mar 2027, 48 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2023
First posted
Aug 31, 2023
StartActual
Mar 1, 2023
Primary completionEst.
Mar 31, 2027
CompletionEst.
Apr 30, 2027
Last update
Mar 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06019975
Responsible party
Sponsor
First posted
Aug 31, 2023
Start date
Mar 1, 2023
Primary completion
Mar 31, 2027 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
Mar 24, 2026

Study contacts

Simone Beretta, MD, PhD
Contact
simone.beretta@unimib.it
+390392333568
Federico Emanuele Pozzi, MD
Contact
federicoemanuele.pozzi@gmail.com
Simone Beretta, MD, PhD
principal investigator · University of Milano Bicocca

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion